 ChromaDex Corp. NASDAQ:CDXC today announced the Company has signed its 200th material transfer agreement MTA through its global ChromaDex External Research Program CERPTM. The program provides Niagen nicotinamide riboside ingredient and placebos at no cost as well as technical expertise and intellectual property support to leading research institutions and universities around the world, advancing the evidence and understanding of the health impact of increasing NAD levels through NR supplementation. The program has resulted in 60 publications to date, including 10 published human trials supporting the safety and efficacy of Niagen. 